1
|
Boulan B, Ravanello C, Peyrel A, Bosc C, Delphin C, Appaix F, Denarier E, Kraut A, Jacquier-Sarlin M, Fournier A, Andrieux A, Gory-Fauré S, Deloulme JC. CRMP4-mediated fornix development involves Semaphorin-3E signaling pathway. eLife 2021; 10:e70361. [PMID: 34860155 PMCID: PMC8683083 DOI: 10.7554/elife.70361] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2021] [Accepted: 12/02/2021] [Indexed: 12/25/2022] Open
Abstract
Neurodevelopmental axonal pathfinding plays a central role in correct brain wiring and subsequent cognitive abilities. Within the growth cone, various intracellular effectors transduce axonal guidance signals by remodeling the cytoskeleton. Semaphorin-3E (Sema3E) is a guidance cue implicated in development of the fornix, a neuronal tract connecting the hippocampus to the hypothalamus. Microtubule-associated protein 6 (MAP6) has been shown to be involved in the Sema3E growth-promoting signaling pathway. In this study, we identified the collapsin response mediator protein 4 (CRMP4) as a MAP6 partner and a crucial effector in Sema3E growth-promoting activity. CRMP4-KO mice displayed abnormal fornix development reminiscent of that observed in Sema3E-KO mice. CRMP4 was shown to interact with the Sema3E tripartite receptor complex within detergent-resistant membrane (DRM) domains, and DRM domain integrity was required to transduce Sema3E signaling through the Akt/GSK3 pathway. Finally, we showed that the cytoskeleton-binding domain of CRMP4 is required for Sema3E's growth-promoting activity, suggesting that CRMP4 plays a role at the interface between Sema3E receptors, located in DRM domains, and the cytoskeleton network. As the fornix is affected in many psychiatric diseases, such as schizophrenia, our results provide new insights to better understand the neurodevelopmental components of these diseases.
Collapse
Affiliation(s)
- Benoît Boulan
- Univ. Grenoble Alpes, Inserm, U1216, CEA, Grenoble Institut NeurosciencesGrenobleFrance
| | - Charlotte Ravanello
- Univ. Grenoble Alpes, Inserm, U1216, CEA, Grenoble Institut NeurosciencesGrenobleFrance
| | - Amandine Peyrel
- Univ. Grenoble Alpes, Inserm, U1216, CEA, Grenoble Institut NeurosciencesGrenobleFrance
| | - Christophe Bosc
- Univ. Grenoble Alpes, Inserm, U1216, CEA, Grenoble Institut NeurosciencesGrenobleFrance
| | - Christian Delphin
- Univ. Grenoble Alpes, Inserm, U1216, CEA, Grenoble Institut NeurosciencesGrenobleFrance
| | - Florence Appaix
- Univ. Grenoble Alpes, Inserm, U1216, CEA, Grenoble Institut NeurosciencesGrenobleFrance
| | - Eric Denarier
- Univ. Grenoble Alpes, Inserm, U1216, CEA, Grenoble Institut NeurosciencesGrenobleFrance
| | - Alexandra Kraut
- Univ. Grenoble Alpes, Inserm, CEA, UMR BioSanté U1292, CNRS, CEAGrenobleFrance
| | | | - Alyson Fournier
- Department of Neurology and Neurosurgery, Montréal Neurological Institute, McGill UniversityMontréalCanada
| | - Annie Andrieux
- Univ. Grenoble Alpes, Inserm, U1216, CEA, Grenoble Institut NeurosciencesGrenobleFrance
| | - Sylvie Gory-Fauré
- Univ. Grenoble Alpes, Inserm, U1216, CEA, Grenoble Institut NeurosciencesGrenobleFrance
| | | |
Collapse
|
2
|
Zhang DN, Liu Y, Li X, Gao Y, Xi FY, Li Y, Zhu GZ. Imbalance Between Soluble and Membrane-Bound CD100 Regulates Monocytes Activity in Hepatitis B Virus-Associated Acute-on-Chronic Liver Failure. Viral Immunol 2021; 34:273-283. [PMID: 33646067 DOI: 10.1089/vim.2020.0311] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
CD100 is an important immune semaphorin that is a secreted and membrane bound protein involved in infectious diseases. However, CD100 expression profile and the regulation to innate immune system in hepatitis B virus (HBV)-associated acute-on-chronic liver failure (ACLF) was not previously reported. The aim of this study was to investigate CD100 level and modulatory function of CD100 to CD14+ monocytes in HBV-ACLF patients. Plasma-soluble CD100 (sCD100) level and membrane-bound CD100 (mCD100) expression on peripheral CD14+ monocytes was analyzed in HBV-ACLF patients. CD14+ monocytes-induced cytotoxicity and CD14+ monocytes-mediated T cell activation in response to CD100 stimulation was also assessed in direct and indirect contact coculture culture systems. HBV-ACLF patients had lower plasma sCD100 and higher mCD100 level on CD14+ monocytes compared with asymptomatic HBV carriers, chronic hepatitis B patients, and controls. CD14+ monocytes from HBV-ACLF patients induced limited target Huh7.5 cell death and secreted less interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and granzyme B in both direct and indirect contact coculture systems compared with controls. Recombinant sCD100 not only enhanced CD14+ monocytes-mediated Huh7.5 cell death and granzyme B secretion, but it also elevated CD14+ monocytes-induced IFN-γ/interleukin-17 production by CD4+ T cells as well as IFN-γ/TNF-α secretion by CD8+ T cells in HBV-ACLF patients. The current data indicated that severe inflammation induced sCD100/mCD100 imbalance to inactivate CD14+ monocytes response, which might be beneficial for the survival of HBV-ACLF patients.
Collapse
Affiliation(s)
- Dong-Na Zhang
- Department of Clinical Laboratory Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China
| | - Ye Liu
- Intensive Care Unit, 964th Hospital of PLA, Changchun, China
| | - Xue Li
- Department of Clinical Laboratory Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China
| | - Ying Gao
- Department of Hematology, Shaanxi Provincial People's Hospital and the Affiliated Hospital of Xi'an Medical University, Xi'an, China
| | - Feng-Yu Xi
- Department of Clinical Laboratory Medicine, and Shaanxi Provincial People's Hospital and the Affiliated Hospital of Xi'an Medical University, Xi'an, China
| | - Yu Li
- Department of Infectious Diseases, Shaanxi Provincial People's Hospital and the Affiliated Hospital of Xi'an Medical University, Xi'an, China
| | - Guang-Ze Zhu
- Department of Clinical Laboratory Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China
| |
Collapse
|
3
|
Westling T, Juraska M, Seaton KE, Tomaras GD, Gilbert PB, Janes H. Methods for comparing durability of immune responses between vaccine regimens in early-phase trials. Stat Methods Med Res 2019; 29:78-93. [PMID: 30623732 DOI: 10.1177/0962280218820881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The ability to produce a long-lasting, or durable, immune response is a crucial characteristic of many highly effective vaccines. A goal of early-phase vaccine trials is often to compare the immune response durability of multiple tested vaccine regimens. One parameter for measuring immune response durability is the area under the mean post-peak log immune response profile. In this paper, we compare immune response durability across vaccine regimens within and between two phase I trials of DNA-primed HIV vaccine regimens, HVTN 094 and HVTN 096. We compare four estimators of this durability parameter and the resulting statistical inferences for comparing vaccine regimens. Two of these estimators use the trapezoid rule as an empirical approximation of the area under the marginal log response curve, and the other two estimators are based on linear and nonlinear models for the marginal mean log response. We conduct a simulation study to compare the four estimators, provide guidance on estimator selection, and use the nonlinear marginal mean model to analyze immunogenicity data from the two HIV vaccine trials.
Collapse
Affiliation(s)
- Ted Westling
- Center for Causal Inference, University of Pennsylvania, PA, USA
| | - Michal Juraska
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Kelly E Seaton
- Duke Human Vaccine Institute, Duke University, Durham, NC, USA
| | - Georgia D Tomaras
- Duke Human Vaccine Institute, Duke University, Durham, NC, USA.,Departments of Surgery, Immunology, and Molecular Genetics and Microbiology, Duke University, Durham, NC, USA
| | - Peter B Gilbert
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Holly Janes
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| |
Collapse
|